“Although artificial intelligence (AI) new drug development ecosystem is being created in Korea, there are still many areas that we are lacking at a global level in terms of manpower or investment scale. Chinese companies that were established around the same time received more than KRW 500 billion in investments, while Korean companies only received KRW 87.8 billion, which delayed their growth. It's time to make efforts to expand this ecosystem while building success stories through step-by-step collaboration.”

Wooyeon Kim, Head of Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA)’s AI ​​New Drug Development Support Center stressed so at the ‘Pharmaceutical-Bio AI Innov